What is the projected market valuation of the Genomics In Cancer Care Market by 2035?

The market is projected to reach approximately 219.79 USD Billion by 2035. Read More

What was the market valuation of the Genomics In Cancer Care Market in 2024?

The market valuation was 46.6 USD Billion in 2024. Read More

What is the expected CAGR for the Genomics In Cancer Care Market from 2025 to 2035?

The expected CAGR during the forecast period 2025 - 2035 is 15.14%. Read More

Which technology segment is anticipated to have the highest valuation by 2035?

The Next-Generation Sequencing (NGS) segment is expected to reach 90.0 USD Billion by 2035. Read More

What are the leading cancer types driving the Genomics In Cancer Care Market?

Breast cancer, lung cancer, and colorectal cancer are key drivers, with colorectal cancer projected to reach 91.74 USD Billion by 2035. Read More

How does the application of diagnostic testing compare to prognostic testing in market valuation?

Diagnostic testing is projected to reach 88.99 USD Billion, while prognostic testing is expected to reach 51.99 USD Billion by 2035. Read More

What sample types are utilized in the Genomics In Cancer Care Market, and which is expected to dominate?

Tissue samples are anticipated to dominate, reaching 87.56 USD Billion by 2035. Read More

Which clinical settings are expected to contribute significantly to the market growth?

Hospital-based laboratories are projected to lead with a valuation of 88.25 USD Billion by 2035. Read More

Who are the key players in the Genomics In Cancer Care Market?

Key players include Illumina, Thermo Fisher Scientific, Roche, and others. Read More

What is the projected valuation of the Comparative Genomic Hybridization (CGH) segment by 2035?

The CGH segment is expected to reach 60.0 USD Billion by 2035. Read More

Genomics In Cancer Care Market

ID: MRFR/LS/29452-HCR

100 Pages

Rahul Gotadki

Last Updated: April 24, 2026

Genomics In Cancer Care Market Research Report By Technology (Next-Generation Sequencing (NGS), Comparative Genomic Hybridization (CGH), Fluorescence In Situ Hybridization (FISH)), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer), By Application (Diagnostic Testing, Prognostic Testing, Treatment Selection, Monitoring Response to Therapy), By Sample Type (Blood, Tissue, Urine), By Clinical Setting (Hospital-Based Laboratories, Commercial Laboratories, Research Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Genomics In Cancer Care Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Technology (USD Billion)
  1. 4.1.1 Next-Generation Sequencing (NGS)
  2. 4.1.2 Comparative Genomic Hybridization (CGH)
  3. 4.1.3 Fluorescence In Situ Hybridization (FISH)
2. 4.2 Healthcare, BY Cancer Type (USD Billion)
  1. 4.2.1 Breast Cancer
  2. 4.2.2 Lung Cancer
  3. 4.2.3 Colorectal Cancer
3. 4.3 Healthcare, BY Application (USD Billion)
  1. 4.3.1 Diagnostic Testing
  2. 4.3.2 Prognostic Testing
  3. 4.3.3 Treatment Selection
  4. 4.3.4 Monitoring Response to Therapy
4. 4.4 Healthcare, BY Sample Type (USD Billion)
  1. 4.4.1 Blood
  2. 4.4.2 Tissue
  3. 4.4.3 Urine
5. 4.5 Healthcare, BY Clinical Setting (USD Billion)
  1. 4.5.1 Hospital-Based Laboratories
  2. 4.5.2 Commercial Laboratories
  3. 4.5.3 Research Institutions
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Illumina (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Thermo Fisher Scientific (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Agilent Technologies (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Qiagen (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bristol-Myers Squibb (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Foundation Medicine (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Myriad Genetics (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Guardant Health (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TECHNOLOGY
4. 6.4 US MARKET ANALYSIS BY CANCER TYPE
5. 6.5 US MARKET ANALYSIS BY APPLICATION
6. 6.6 US MARKET ANALYSIS BY SAMPLE TYPE
7. 6.7 US MARKET ANALYSIS BY CLINICAL SETTING
8. 6.8 CANADA MARKET ANALYSIS BY TECHNOLOGY
9. 6.9 CANADA MARKET ANALYSIS BY CANCER TYPE
10. 6.10 CANADA MARKET ANALYSIS BY APPLICATION
11. 6.11 CANADA MARKET ANALYSIS BY SAMPLE TYPE
12. 6.12 CANADA MARKET ANALYSIS BY CLINICAL SETTING
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TECHNOLOGY
15. 6.15 GERMANY MARKET ANALYSIS BY CANCER TYPE
16. 6.16 GERMANY MARKET ANALYSIS BY APPLICATION
17. 6.17 GERMANY MARKET ANALYSIS BY SAMPLE TYPE
18. 6.18 GERMANY MARKET ANALYSIS BY CLINICAL SETTING
19. 6.19 UK MARKET ANALYSIS BY TECHNOLOGY
20. 6.20 UK MARKET ANALYSIS BY CANCER TYPE
21. 6.21 UK MARKET ANALYSIS BY APPLICATION
22. 6.22 UK MARKET ANALYSIS BY SAMPLE TYPE
23. 6.23 UK MARKET ANALYSIS BY CLINICAL SETTING
24. 6.24 FRANCE MARKET ANALYSIS BY TECHNOLOGY
25. 6.25 FRANCE MARKET ANALYSIS BY CANCER TYPE
26. 6.26 FRANCE MARKET ANALYSIS BY APPLICATION
27. 6.27 FRANCE MARKET ANALYSIS BY SAMPLE TYPE
28. 6.28 FRANCE MARKET ANALYSIS BY CLINICAL SETTING
29. 6.29 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
30. 6.30 RUSSIA MARKET ANALYSIS BY CANCER TYPE
31. 6.31 RUSSIA MARKET ANALYSIS BY APPLICATION
32. 6.32 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE
33. 6.33 RUSSIA MARKET ANALYSIS BY CLINICAL SETTING
34. 6.34 ITALY MARKET ANALYSIS BY TECHNOLOGY
35. 6.35 ITALY MARKET ANALYSIS BY CANCER TYPE
36. 6.36 ITALY MARKET ANALYSIS BY APPLICATION
37. 6.37 ITALY MARKET ANALYSIS BY SAMPLE TYPE
38. 6.38 ITALY MARKET ANALYSIS BY CLINICAL SETTING
39. 6.39 SPAIN MARKET ANALYSIS BY TECHNOLOGY
40. 6.40 SPAIN MARKET ANALYSIS BY CANCER TYPE
41. 6.41 SPAIN MARKET ANALYSIS BY APPLICATION
42. 6.42 SPAIN MARKET ANALYSIS BY SAMPLE TYPE
43. 6.43 SPAIN MARKET ANALYSIS BY CLINICAL SETTING
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY CANCER TYPE
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY CLINICAL SETTING
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TECHNOLOGY
51. 6.51 CHINA MARKET ANALYSIS BY CANCER TYPE
52. 6.52 CHINA MARKET ANALYSIS BY APPLICATION
53. 6.53 CHINA MARKET ANALYSIS BY SAMPLE TYPE
54. 6.54 CHINA MARKET ANALYSIS BY CLINICAL SETTING
55. 6.55 INDIA MARKET ANALYSIS BY TECHNOLOGY
56. 6.56 INDIA MARKET ANALYSIS BY CANCER TYPE
57. 6.57 INDIA MARKET ANALYSIS BY APPLICATION
58. 6.58 INDIA MARKET ANALYSIS BY SAMPLE TYPE
59. 6.59 INDIA MARKET ANALYSIS BY CLINICAL SETTING
60. 6.60 JAPAN MARKET ANALYSIS BY TECHNOLOGY
61. 6.61 JAPAN MARKET ANALYSIS BY CANCER TYPE
62. 6.62 JAPAN MARKET ANALYSIS BY APPLICATION
63. 6.63 JAPAN MARKET ANALYSIS BY SAMPLE TYPE
64. 6.64 JAPAN MARKET ANALYSIS BY CLINICAL SETTING
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY CANCER TYPE
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY CLINICAL SETTING
70. 6.70 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
71. 6.71 MALAYSIA MARKET ANALYSIS BY CANCER TYPE
72. 6.72 MALAYSIA MARKET ANALYSIS BY APPLICATION
73. 6.73 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE
74. 6.74 MALAYSIA MARKET ANALYSIS BY CLINICAL SETTING
75. 6.75 THAILAND MARKET ANALYSIS BY TECHNOLOGY
76. 6.76 THAILAND MARKET ANALYSIS BY CANCER TYPE
77. 6.77 THAILAND MARKET ANALYSIS BY APPLICATION
78. 6.78 THAILAND MARKET ANALYSIS BY SAMPLE TYPE
79. 6.79 THAILAND MARKET ANALYSIS BY CLINICAL SETTING
80. 6.80 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
81. 6.81 INDONESIA MARKET ANALYSIS BY CANCER TYPE
82. 6.82 INDONESIA MARKET ANALYSIS BY APPLICATION
83. 6.83 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE
84. 6.84 INDONESIA MARKET ANALYSIS BY CLINICAL SETTING
85. 6.85 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
86. 6.86 REST OF APAC MARKET ANALYSIS BY CANCER TYPE
87. 6.87 REST OF APAC MARKET ANALYSIS BY APPLICATION
88. 6.88 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE
89. 6.89 REST OF APAC MARKET ANALYSIS BY CLINICAL SETTING
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
92. 6.92 BRAZIL MARKET ANALYSIS BY CANCER TYPE
93. 6.93 BRAZIL MARKET ANALYSIS BY APPLICATION
94. 6.94 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE
95. 6.95 BRAZIL MARKET ANALYSIS BY CLINICAL SETTING
96. 6.96 MEXICO MARKET ANALYSIS BY TECHNOLOGY
97. 6.97 MEXICO MARKET ANALYSIS BY CANCER TYPE
98. 6.98 MEXICO MARKET ANALYSIS BY APPLICATION
99. 6.99 MEXICO MARKET ANALYSIS BY SAMPLE TYPE
100. 6.100 MEXICO MARKET ANALYSIS BY CLINICAL SETTING
101. 6.101 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
102. 6.102 ARGENTINA MARKET ANALYSIS BY CANCER TYPE
103. 6.103 ARGENTINA MARKET ANALYSIS BY APPLICATION
104. 6.104 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE
105. 6.105 ARGENTINA MARKET ANALYSIS BY CLINICAL SETTING
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY CANCER TYPE
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY CLINICAL SETTING
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY CANCER TYPE
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY CLINICAL SETTING
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY CANCER TYPE
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY CLINICAL SETTING
122. 6.122 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
123. 6.123 REST OF MEA MARKET ANALYSIS BY CANCER TYPE
124. 6.124 REST OF MEA MARKET ANALYSIS BY APPLICATION
125. 6.125 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE
126. 6.126 REST OF MEA MARKET ANALYSIS BY CLINICAL SETTING
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY CANCER TYPE, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY CANCER TYPE, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY CLINICAL SETTING, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY CLINICAL SETTING, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.2.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.2.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.3.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.3.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.4.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.4.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.5.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.5.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.6.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.6.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.7.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.7.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.8.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.8.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.9.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.9.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.10.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.10.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.11.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.11.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.12.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.12.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.13.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.13.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.14.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.14.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.15.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.15.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.16.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.16.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.17.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.17.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.18.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.18.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.19.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.19.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.20.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.20.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.21.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.21.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.22.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.22.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.23.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.23.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.24.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.24.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.25.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.25.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.26.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.26.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.27.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.27.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.28.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.28.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.29.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.29.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.30.2 BY CANCER TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY APPLICATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  5. 7.30.5 BY CLINICAL SETTING, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Technology (USD Billion, 2025-2035)

Next-Generation Sequencing (NGS)
Comparative Genomic Hybridization (CGH)
Fluorescence In Situ Hybridization (FISH)

Healthcare By Cancer Type (USD Billion, 2025-2035)

Breast Cancer
Lung Cancer
Colorectal Cancer

Healthcare By Application (USD Billion, 2025-2035)

Diagnostic Testing
Prognostic Testing
Treatment Selection
Monitoring Response to Therapy

Healthcare By Sample Type (USD Billion, 2025-2035)

Blood
Tissue
Urine

Healthcare By Clinical Setting (USD Billion, 2025-2035)

Hospital-Based Laboratories
Commercial Laboratories
Research Institutions

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓